$55.22
-1.29%
N/A-$0.72
Healthcare
Biotechnology
NASDAQ
활발히 거래 중
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial ...
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial ...
Apitegromab is a lead therapeutic candidate that functions as a selective inhibitor of latent myostatin activation. It is currently being developed for various indications, including Spinal Muscular Atrophy (SMA) in both pediatric and adult populations, as well as Facioscapulohumeral Muscular Dystrophy (FSHD).
가격대: N/A (Investigational)
페인 포인트: Muscle weakness, atrophy, and loss of physical function associated with chronic neuromuscular conditions.
솔루션: Inhibits the activation of myostatin, a protein that restricts muscle growth, thereby potentially promoting muscle mass and function.
대상 사용자: Patients (children and adults) suffering from spinal muscular atrophy and other rare neuromuscular diseases.
SRK-181 is an investigational agent designed to inhibit latent TGFβ1. It aims to tackle solid tumors that have shown resistance to existing checkpoint inhibitors such as anti-PD-1 or anti-PD-L1 therapies.
가격대: N/A (Investigational)
페인 포인트: Resistance to standard-of-care checkpoint inhibitor immunotherapies in cancer patients.
솔루션: Modulates the tumor microenvironment by targeting latent TGFβ1, potentially enhancing the efficacy of anti-tumor immune responses.
대상 사용자: Patients with locally advanced or metastatic solid tumors unresponsive to conventional immunotherapies.
SRK-439 is a next-generation anti-latent myostatin program designed for subcutaneous administration to address rare neuromuscular indications.
가격대: N/A (Investigational)
페인 포인트: Limited treatment options for specific rare muscle-wasting conditions.
솔루션: Targeted inhibition of latent myostatin via a convenient subcutaneous delivery method.
대상 사용자: Patients with specific rare neuromuscular diseases.
SRK-373 targets LTBP1 and LTBP3 to selectively inhibit latent TGFβ1 activation in the context of fibrosis. Developed in collaboration with Gilead Sciences.
가격대: N/A (Investigational)
페인 포인트: Progression of tissue fibrosis in chronic disease states.
솔루션: Selective inhibition of TGFβ1 activation to mitigate fibrotic pathways.
대상 사용자: Patients suffering from fibrotic diseases.
SRK-256 targets Repulsive Guidance Molecule (RGM) proteins, specifically Hemojuvelin (HJV), to modulate iron metabolism in conditions characterized by iron-restricted anemia.
가격대: N/A (Investigational)
페인 포인트: Iron-restricted anemia symptoms and underlying biological dysfunction.
솔루션: Regulation of iron homeostasis by inhibiting RGMc/HJV pathways.
대상 사용자: Patients diagnosed with iron-restricted anemia.